Search Videos and More
News
New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs
Multiple acquired resistance mechanisms discovered for cancers with KRASG12C mutation after treatment with KRASG12C inhibitors.
Podcast
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.
News
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch
An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows.
News
Red Meat Consumption May Promote DNA Damage-associated Mutations in Patients with Colorectal Cancer
Genetic mutations indicative of DNA damage were associated with high red meat consumption and increased cancer-related mortality in patients with colorectal cancer, according to a study led by Dana-Farber Cancer Institute researchers and published in Cancer Discovery, a journal of the American Association for Cancer Research.
News
“45 is the New 50” as Age for Colorectal Cancer Screening is Lowered
Prompted by a recent alarming rise in cases of colorectal cancer in people younger than 50, an independent expert panel has recommended that individuals of average risk for the disease begin screening exams at 45 years of age instead of the traditional 50.
Video
COVID-19 Vaccine Study in Cancer Patients
Dana-Farber researchers are leading a study that looks at the effects of the COVID-19 vaccine in cancer patients.
News
New ‘Druggable’ Genetic Targets Identified in Rare Type of Bile Duct Cancer
Scientists are beginning to make inroads into treating cholangiocarcinoma, a rare, lethal cancer of the bile ducts, with precision drugs. Last year, the first targeted drug for some patients with the disease was approved.
News
Study Finds Lower Mortality Rate for Men at High Risk for Death from Prostate Cancer Who Received Early Postoperative Radiation Therapy
In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery
News
2021 ASCO Highlights
Dana-Farber physician-scientists shared research and clinical advances at the 2021 Annual Meeting of the American Society of Clinical Oncologists (ASCO).
News
Hematologic Malignancies CME
The care of patients with hematologic malignancies is evolving rapidly. These video highlights will discuss new developments in the diagnosis and treatment of hematologic malignancies, as presented at the 2020 Annual Meeting of the American Society of Hematology (ASH).
News
Immunotherapy Drug Delays Recurrence in Kidney Cancer Patients
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
News
Dana-Farber Scientists Work to Accelerate Development for Blood Tests for Ovarian Cancer
A new partnership between researchers at Dana-Farber Cancer Institute and University College London (UCL) may prove decisive in the quest to develop the first blood test for early-stage ovarian cancer.